TheStreet reaffirmed their buy rating on shares of Medtronic (NYSE: MDT) in a research note released on Monday morning, Analyst Ratings Network reports.

“Medtronic (MDT) has been reiterated by TheStreet Ratings as a buy with a ratings score of A-. The company’s strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, growth in earnings per share, increase in net income and attractive valuation levels. Although no company is perfect, currently we do not see any significant weaknesses which are likely to detract from the generally positive outlook.”

,” TheStreet’s analyst commented.

TheStreet has also updated their ratings on a number of other healthcare stocks in the last week. The firm downgraded shares of ArthroCare Co. from a buy rating to a hold rating. Also, TheStreet downgraded shares of Align Tech from a buy rating to a hold rating.

MDT has been the subject of a number of other recent research reports. Analysts at Deutsche Bank raised their price target on shares of Medtronic from $46.00 to $51.00 in a research note to investors on Friday, April 12th. They now have a hold rating on the stock. Separately, analysts at JPMorgan Chase reiterated a neutral rating on shares of Medtronic in a research note to investors on Thursday, April 11th. They now have a $49.00 price target on the stock. Finally, analysts at Zacks reiterated a neutral rating on shares of Medtronic in a research note to investors on Friday, April 5th. They now have a $49.00 price target on the stock.

Twelve equities research analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. The company has a consensus rating of Hold and an average target price of $49.38.

Medtronic (NYSE: MDT) traded down 0.36% on Monday, hitting $46.42. Medtronic has a 1-year low of $35.67 and a 1-year high of $47.98. The stock’s 50-day moving average is currently $46.24. The company has a market cap of $47.061 billion and a price-to-earnings ratio of 13.78.

Medtronic, Inc. (NYSE: MDT) is engaged in medical technology – alleviating pain, restoring health, and extending life for millions of people worldwide.

To view TheStreet’s full report, visit www.thestreetratings.com

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.